CY1125082T1 - Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα - Google Patents

Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα

Info

Publication number
CY1125082T1
CY1125082T1 CY20221100210T CY221100210T CY1125082T1 CY 1125082 T1 CY1125082 T1 CY 1125082T1 CY 20221100210 T CY20221100210 T CY 20221100210T CY 221100210 T CY221100210 T CY 221100210T CY 1125082 T1 CY1125082 T1 CY 1125082T1
Authority
CY
Cyprus
Prior art keywords
methods related
substituted triazoles
treatment
pharmaceutically acceptable
disclosed
Prior art date
Application number
CY20221100210T
Other languages
Greek (el)
English (en)
Inventor
John P. Williams
Deborah Slee
Manisha Moorjani
Neil J. ASHWEEK
Original Assignee
Neurocrine Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences, Inc. filed Critical Neurocrine Biosciences, Inc.
Publication of CY1125082T1 publication Critical patent/CY1125082T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/041,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CY20221100210T 2015-01-30 2022-03-16 Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα CY1125082T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562110415P 2015-01-30 2015-01-30
US201562259314P 2015-11-24 2015-11-24
PCT/US2016/015740 WO2016123533A1 (en) 2015-01-30 2016-01-29 Substituted triazoles and methods relating thereto

Publications (1)

Publication Number Publication Date
CY1125082T1 true CY1125082T1 (el) 2023-06-09

Family

ID=55305123

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100210T CY1125082T1 (el) 2015-01-30 2022-03-16 Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα

Country Status (22)

Country Link
US (4) US9718789B2 (enExample)
EP (1) EP3250563B1 (enExample)
JP (1) JP6728198B2 (enExample)
KR (1) KR102575601B1 (enExample)
CN (1) CN107406420B (enExample)
AU (1) AU2016211292B2 (enExample)
BR (1) BR112017016488A2 (enExample)
CA (1) CA2975474C (enExample)
CY (1) CY1125082T1 (enExample)
DK (1) DK3250563T3 (enExample)
ES (1) ES2905878T3 (enExample)
HR (1) HRP20220327T1 (enExample)
HU (1) HUE058156T2 (enExample)
IL (1) IL253705B (enExample)
LT (1) LT3250563T (enExample)
MX (1) MX378932B (enExample)
PL (1) PL3250563T3 (enExample)
PT (1) PT3250563T (enExample)
RS (1) RS62862B1 (enExample)
RU (1) RU2718049C2 (enExample)
SI (1) SI3250563T1 (enExample)
WO (1) WO2016123533A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40281B1 (fr) 2014-06-03 2018-11-30 Idorsia Pharmaceuticals Ltd Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EP3194374B1 (en) 2014-09-15 2018-08-01 Idorsia Pharmaceuticals Ltd Triazole compounds as t-type calcium channel blockers
SI3250563T1 (sl) 2015-01-30 2022-04-29 Neurocrine Biosciences, Inc. Substituirani triazoli in z njimi povezani postopki
EP3554490B1 (en) 2016-12-16 2022-02-16 Idorsia Pharmaceuticals Ltd Pharmaceutical combination comprising a t-type calcium channel blocker
EP3577099B1 (en) 2017-02-06 2024-01-24 Idorsia Pharmaceuticals Ltd A novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropanes
KR102298546B1 (ko) * 2018-10-18 2021-09-08 에이치케이이노엔 주식회사 신규한 n-(이소프로필-트리아졸릴)피리디닐)-헤테로아릴-카르복사미드 유도체 및 이의 용도
CN110669017B (zh) * 2019-10-11 2023-08-04 成都麻沸散医药科技有限公司 多取代三唑甲酸酯类衍生物及其用途
CN115974799B (zh) * 2021-10-14 2024-08-13 成都百裕制药股份有限公司 氨基甲酸酯取代的醇衍生物及其在医药上的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) * 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
TW513301B (en) * 1999-03-01 2002-12-11 Novartis Ag Pharmaceutical composition for treatment of neuropathic pain and affective and attention disorders
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
EP1829867A1 (en) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Imidazole compounds having pharmaceutical activity towards the sigma receptor
EP1921073A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
EP1921071A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
EP2752411A1 (en) * 2013-01-07 2014-07-09 Laboratorios Del Dr. Esteve, S.A. 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
SI3250563T1 (sl) 2015-01-30 2022-04-29 Neurocrine Biosciences, Inc. Substituirani triazoli in z njimi povezani postopki

Also Published As

Publication number Publication date
CA2975474C (en) 2023-06-13
NZ734260A (en) 2024-01-26
US20190169137A1 (en) 2019-06-06
JP2018503661A (ja) 2018-02-08
KR20170106470A (ko) 2017-09-20
AU2016211292B2 (en) 2020-05-07
RU2017130474A (ru) 2019-02-28
US10738017B2 (en) 2020-08-11
CA2975474A1 (en) 2016-08-04
IL253705B (en) 2020-09-30
RU2718049C2 (ru) 2020-03-30
LT3250563T (lt) 2022-04-11
PT3250563T (pt) 2022-02-09
AU2016211292A1 (en) 2017-08-24
US10138214B2 (en) 2018-11-27
MX378932B (es) 2025-03-10
HRP20220327T1 (hr) 2022-05-13
MX2017009824A (es) 2017-11-02
CN107406420B (zh) 2020-11-06
JP6728198B2 (ja) 2020-07-22
IL253705A0 (en) 2017-09-28
DK3250563T3 (da) 2022-01-31
EP3250563A1 (en) 2017-12-06
US20170349558A1 (en) 2017-12-07
US11021449B2 (en) 2021-06-01
RU2017130474A3 (enExample) 2019-06-11
US20160221968A1 (en) 2016-08-04
KR102575601B1 (ko) 2023-09-05
HUE058156T2 (hu) 2022-07-28
ES2905878T3 (es) 2022-04-12
US20200399229A1 (en) 2020-12-24
PL3250563T3 (pl) 2022-05-02
BR112017016488A2 (pt) 2018-04-10
RS62862B1 (sr) 2022-02-28
US9718789B2 (en) 2017-08-01
SI3250563T1 (sl) 2022-04-29
EP3250563B1 (en) 2022-01-12
WO2016123533A1 (en) 2016-08-04
CN107406420A (zh) 2017-11-28

Similar Documents

Publication Publication Date Title
CY1125082T1 (el) Υποκατεστημενα τριαζολια και μεθοδοι που σχετιζονται με αυτα
CY1124173T1 (el) Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1124496T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
CY1124620T1 (el) Οξυστερολες και μεθοδοι χρησης αυτων
UY37854A (es) Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos
CL2018001469A1 (es) Derivados de oxadiazol microbicidas.
CY1119771T1 (el) Ενωσεις αμινοπυριμιδινυλιου ως αναστολεις toy jak
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX383051B (es) Compuestos que inhiben eif4a y métodos relacionados a los mismos.
CR20140413A (es) Inhibidores de serina/treonina cinasa
CY1119642T1 (el) Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
CY1125198T1 (el) Ενωσεις και αναλογα 1-ετεροκυκλικου ισοχρωμανυλιου για την αντιμετωπιση διαταραχων του κνς
TN2018000393A1 (en) Pegylated carfilzomib compounds
CU20170007A7 (es) Compuestos de imidazopiridazina
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
JO3372B1 (ar) مشتقات 5-بنزيل إيزوكينولين لعلاج أمراض القلب والأوعية الدموية
TN2017000342A1 (en) Novel cyclopropabenzofuranyl pyridopyrazinediones
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
CY1120432T1 (el) Παραγωγα του φωσφοραμιδικου οξεος του 5-[5-φαινυλ-4-(πυριδιν-2-υλομεθυδαμινο)κιναζολιν-2-υλ]πυριδινο-3-σουλφοναμιδιου
CY1118552T1 (el) Νεα παραγωγα πυριμιδινης ως αναστολεις φωσφοδιεστερασης 10 (pde-10)
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease